Selective SIRT2 inhibitors as promising anticancer therapeutics: An update from 2016 to 2020

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Sirtuin 2 (SIRT2) is a human sirtuin involved in diverse biological processes.
• SIRT2 is recognized as a potential biomarker in various cancer types.
• While SIRT2's role in tumorigenesis is debated, its inhibition consistently halts cancer cell proliferation.

Purpose of the Study:

• To review current selective SIRT2 inhibitors.
• To discuss their antiproliferative effects on cancer cells.
• To highlight therapeutic potential in oncology.

Main Methods:

• Literature review of published studies on SIRT2 inhibitors.
• Analysis of reported antiproliferative activities.
• Synthesis of findings on selective SIRT2 modulators.

Main Results:

• Pharmacological inhibition of SIRT2 leads to universal growth inhibition across cancer cell types.
• Selective SIRT2 inhibitors demonstrate significant antiproliferative effects.
• Numerous successful discoveries of SIRT2 modulators have been reported.

Conclusions:

• Selective SIRT2 inhibitors represent a promising therapeutic strategy for a broad spectrum of tumors.
• Targeted inhibition of SIRT2 offers a viable approach for cancer treatment.
• Further research into SIRT2 modulators could yield novel anti-cancer drugs.